The FDA has approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis).

“We are proud to bring ULTOMIRIS to patients suffering from this devastating disease less than a year after reporting our positive Phase 3 data,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion.

BioCT congratulates Alexion! Their executive staff is located in Boston, but more than 450 employees are doing great research and development in New Haven.

Alexion press release
article in New Haven Register